沙美特罗氟替卡松气雾剂治疗轻、中度慢性阻塞性肺疾病稳定期疗效分析  

Therapeutic effect of salmeterol-fluticasone aerosol on mild to moderate chronic obstructive pulmonary disease

作　　者：曹玉海[1] Cao Yuhai(Department of Respiratory Medicine,the General Hospital of Shanxi Tongmei Group,Datong,Shanxi 037003,China)

机构地区：[1]山西同煤集团总医院呼吸内科,大同037003

出　　处：《中国基层医药》2019年第21期2565-2568,共4页Chinese Journal of Primary Medicine and Pharmacy

基　　金：山西省重点研发计划(指南)项目(201603D321054)。

摘　　要：目的分析沙美特罗氟替卡松气雾剂治疗轻、中度慢性阻塞性肺疾病稳定期的临床疗效.方法选择山西同煤集团总医院2017年2月至2018年2月治疗的轻、中度慢性阻塞性肺疾病稳定期患者68例为观察对象,采用随机数字表法将患者分为对照组34例、观察组34例.对照组采用沙丁胺醇气雾剂吸入治疗,观察组采用沙美特罗氟替卡松气雾剂吸入治疗,两组疗程均为12周.比较两组患者的临床疗效、肺功能改善情况、6 min步行距离、血氧饱和度和心率的变化.结果观察组总有效率为97.06%(33/34),明显高于对照组的73.53%(25/34)(χ2=7.503,P<0.05).治疗前,两组第1秒用力呼气容积占预计值百分比(FEV1%)、第1秒用力呼气容积占用力肺活量百分比(FEV1/FVC)、1秒用力呼吸容积(FEV1)、血氧饱和度、心率、6 min步行距离差异均无统计学意义(均P>0.05);治疗后,观察组FEV1%、FEV1/FVC、FEV1分别为(65.48±4.06)%、(74.66±8.12)%、(1.99±0.55)L,均高于对照组的(63.55±6.14)%、(70.85±7.56)%、(1.71±0.52)L(t=2.321、2.002、2.157,均P<0.05);观察组血氧饱和度、心率、6 min步行距离分别为(92.27±1.83)%、(80.55±4.08)次/min、(263.35±28.73)m,对照组分别为(88.52±2.06)%、(91.43±5.16)次/min、(231.95±22.69)m,两组差异均有统计学意义(t=7.936、9.644、5.001,均P<0.05).结论沙美特罗氟替卡松气雾剂吸入治疗轻、中度慢性阻塞性肺疾病稳定期有较好的临床疗效,可明显改善患者的肺功能.Objective To analyze the clinical efficacy of salmeterol-fluticasone aerosol in the treatment of mild to moderate chronic obstructive pulmonary disease(COPD).Methods From February 2017 to February 2018,68 patients with mild to moderate COPD treated in the General Hospital of Shanxi Tongmei Group were selected in the study.The patients were divided into control group(34 cases)and observation group(34 cases)by random number table method.The control group was treated with salbutamol aerosol inhalation,while the observation group was treated with salmeterol and fluticasone aerosol inhalation.Both two groups were treated for 12 weeks.The clinical efficacy,improvement of pulmonary function,6-minute walking distance,oxygen saturation and heart rate were compared between the two groups.Results The total effective rate of the observation group was 97.06%(33/34),which was significantly higher than that of the control group[73.53%(25/34)](χ2=7.503,P<0.05).Before treatment,FEV1%,FEV1/FVC(percentage of forced expiratory volume in 1 second forced vital capacity),FEV1(1 second hard breathing volume),blood oxygen saturation,heart rate and 6 min walking distance had no statistically significant differences between the two groups(all P>0.05).After treatment,the FEV1,FEV1/FVC,FEV1%in the observation group were(65.48±4.06)%,(74.66±8.12)%,(1.99±0.55)L,respectively,which were significantly higher than those in the control group[(63.55±6.14)%,(70.85±7.56)%,(1.71±0.52)L](t=2.321,2.002,2.157,all P<0.05).The oxygen saturation,heart rate and 6-minute walking distance in the observation group were(92.27±1.83)%,(80.55±4.08)times/min and(263.35±28.73)m,respectively,which in the control group were(88.52±2.06)%,(91.43±5.16)times/min and(231.95±22.69)m,respectively,and there were statistically significant differences between the two groups(t=7.936,9.644,5.001,all P<0.05).Conclusion Salmeterol and fluticasone aerosol inhalation has good clinical efficacy in the treatment of mild to moderate COPD,and can significantly improve the lung

关 键 词：肺疾病 慢性阻塞性 沙丁胺醇 沙美特罗氟替卡松 气雾剂 投药 吸入 血气监测 经皮 心率 呼吸功能试验 

分 类 号：R56[医药卫生—呼吸系统]